Home
News
Create
Screeners
Insights
Corona Remedies
1,577.
30
+12.80
(+0.82%)
Market Cap
₹9,646.78 Cr
PE Ratio
55.67
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+0.82%
1M
-3.32%
6M
+9.66%
1Y
+9.66%
5Y
+9.66%
View Company Insights
Latest news about Corona Remedies
Corona Remedies Limited Files Quarterly Regulatory Certificate for Q4 FY26
7 days ago
Corona Remedies Limited submitted its quarterly regulatory certificate for Q4 FY26 ended March 31, 2026, to BSE and NSE on April 07, 2026. The certificate, issued by registrar Bigshare Services Private Limited, confirms that SEBI Regulation 74(5) is not applicable as all shares remain in demat form with no rematerialisation or dematerialisation requests during the quarter. This filing represents routine compliance with SEBI depositories regulations for the pharmaceutical company.
Corona Remedies Reports 87% OCF to EBITDA Ratio, Eyes Further Acquisitions
7 days ago
Corona Remedies Reports ₹112 Crore Cash Reserves, Sets 20-25% Growth Target for Wpladone
7 days ago
CORONA Remedies Limited Acquires Wokadine® Brand from Dr. Reddy's Laboratories in Strategic Deal
Mar 31, 2026
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO